Targeting of C-type lectin-like receptor 2 or P2Y12 for the prevention of platelet activation by immunotherapeutic CpG oligodeoxynucleotides: comment

U. Flierl; T. L. Nero; B. Lim; R. K. Andrews; M. W. Parker; E. E. Gardiner; K. Peter

doi:10.1111/jth.13877

Targeting of C-type lectin-like receptor 2 or P2Y12 for the prevention of platelet activation by immunotherapeutic CpG oligodeoxynucleotides: comment

U. Flierl^*, T. L. Nero, B. Lim, R. K. Andrews, M. W. Parker, E. E. Gardiner, K. Peter

^*Corresponding author for this work

Research output: Contribution to journal › Letter › peer-review

2 Citations (Scopus)

Abstract

Essentials CpG oligodeoxynucleotide (ODN) immuotherapeutics cause undesired platelet activating effects. It is crucial to understand the mechanisms of these effects to identify protective strategies. CpG ODN-induced platelet activation depends on C-type lectin-like receptor 2 (CLEC-2) and P2Y12. Targeting CLEC-2 or P2Y12 fully prevents CpG ODN-induced platelet activation and thrombosis.

Original language	English
Pages (from-to)	181-185
Number of pages	5
Journal	Journal of Thrombosis and Haemostasis
Volume	16
Issue number	1
DOIs	https://doi.org/10.1111/jth.13877
Publication status	Published - Jan 2018

Access to Document

10.1111/jth.13877

Cite this

@article{75b29d798077450f90d0b846d18f21ee,

title = "Targeting of C-type lectin-like receptor 2 or P2Y12 for the prevention of platelet activation by immunotherapeutic CpG oligodeoxynucleotides: comment",

abstract = "Essentials CpG oligodeoxynucleotide (ODN) immuotherapeutics cause undesired platelet activating effects. It is crucial to understand the mechanisms of these effects to identify protective strategies. CpG ODN-induced platelet activation depends on C-type lectin-like receptor 2 (CLEC-2) and P2Y12. Targeting CLEC-2 or P2Y12 fully prevents CpG ODN-induced platelet activation and thrombosis.",

author = "U. Flierl and Nero, {T. L.} and B. Lim and Andrews, {R. K.} and Parker, {M. W.} and Gardiner, {E. E.} and K. Peter",

year = "2018",

month = jan,

doi = "10.1111/jth.13877",

language = "English",

volume = "16",

pages = "181--185",

journal = "Journal of Thrombosis and Haemostasis",

issn = "1538-7933",

publisher = "Elsevier B.V.",

number = "1",

}

TY - JOUR

T1 - Targeting of C-type lectin-like receptor 2 or P2Y12 for the prevention of platelet activation by immunotherapeutic CpG oligodeoxynucleotides

T2 - comment

AU - Flierl, U.

AU - Nero, T. L.

AU - Lim, B.

AU - Andrews, R. K.

AU - Parker, M. W.

AU - Gardiner, E. E.

AU - Peter, K.

PY - 2018/1

Y1 - 2018/1

N2 - Essentials CpG oligodeoxynucleotide (ODN) immuotherapeutics cause undesired platelet activating effects. It is crucial to understand the mechanisms of these effects to identify protective strategies. CpG ODN-induced platelet activation depends on C-type lectin-like receptor 2 (CLEC-2) and P2Y12. Targeting CLEC-2 or P2Y12 fully prevents CpG ODN-induced platelet activation and thrombosis.

AB - Essentials CpG oligodeoxynucleotide (ODN) immuotherapeutics cause undesired platelet activating effects. It is crucial to understand the mechanisms of these effects to identify protective strategies. CpG ODN-induced platelet activation depends on C-type lectin-like receptor 2 (CLEC-2) and P2Y12. Targeting CLEC-2 or P2Y12 fully prevents CpG ODN-induced platelet activation and thrombosis.

UR - http://www.scopus.com/inward/record.url?scp=85040027838&partnerID=8YFLogxK

U2 - 10.1111/jth.13877

DO - 10.1111/jth.13877

M3 - Letter

SN - 1538-7933

VL - 16

SP - 181

EP - 185

JO - Journal of Thrombosis and Haemostasis

JF - Journal of Thrombosis and Haemostasis

IS - 1

ER -

Targeting of C-type lectin-like receptor 2 or P2Y12 for the prevention of platelet activation by immunotherapeutic CpG oligodeoxynucleotides: comment

Abstract

Access to Document

Other files and links

Fingerprint

Cite this